With the recent proliferation of high-cost drugs threatening many states’ Medicaid budgets, some of those states have attempted to impose limits on the use of those drugs.

But are those limits legal?

That is the question addressed in a new report in the Annals of Internal Medicine, which notes that

Current restrictions seem to violate federal Medicaid law, which requires states to cover drugs consistent with their U.S. Food and Drug Administration labels.

So are those limits legal? Or will patients and their advocates have grounds to challenge limits to their access to potentially life-saving or life-improving drugs?

Learn more about this situation in the new report “Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States” here, on the web site of the Annals of Internal Medicine.